(Q43012056)

12 November 2017

title

The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone (English)

1 reference

12 November 2017

0 references

Nikolina Jovanović

1

1 reference

12 November 2017

Nada Božina

2

1 reference

12 November 2017

Mila Lovrić

3

1 reference

12 November 2017

Vesna Medved

4

1 reference

12 November 2017

Miro Jakovljević

5

1 reference

12 November 2017

Alma Mihaljević Peleš

6

1 reference

12 November 2017

publication date

19 June 2010

1 reference

European Journal of Clinical Pharmacology

12 November 2017

published in

1 reference

12 November 2017

volume

66

1 reference

12 November 2017

issue

11

1 reference

12 November 2017

page(s)

1109-1117

1 reference

ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.

12 November 2017

cites work

1 reference

12 December 2020

Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes

1 reference

12 December 2020

MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes

1 reference

12 December 2020

In vitro P-glycoprotein affinity for atypical and conventional antipsychotics

1 reference

12 December 2020

Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients

1 reference

12 December 2020

Clinical significance of a CYP2D6 poor metabolizer--a patient with schizophrenia on risperidone treatment

1 reference

12 December 2020

No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients

1 reference

12 December 2020

Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects

1 reference

12 December 2020

A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.

1 reference

12 December 2020

Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research

1 reference

12 December 2020

Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance

1 reference

12 December 2020

Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population

1 reference

12 December 2020

Genotyping of the triallelic variant G2677T/A in MDR1 using LightCycler with locked-nucleic-acid-modified hybridization probes.

1 reference

12 December 2020

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

1 reference

12 December 2020

Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction

1 reference

12 December 2020

Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone

1 reference

12 December 2020

Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients

1 reference

12 December 2020

Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes.

1 reference

12 December 2020

Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended

1 reference

12 December 2020

Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

1 reference

12 December 2020

MDR1 gene polymorphisms and response to acute risperidone treatment

1 reference

12 December 2020

Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4

1 reference

12 December 2020

Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection

1 reference

12 December 2020

Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia

1 reference

12 December 2020

Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study

1 reference

12 December 2020

A rating scale for extrapyramidal side effects

1 reference

12 December 2020

Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected

1 reference

12 December 2020

The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation

1 reference

12 December 2020

10.1007/S00228-010-0850-1

Identifiers

DOI

1 reference

12 November 2017

1 reference